With dengue continuing to pose one of India’s most significant public health challenges, Fortis Healthcare and Takeda today announced the launch of ‘Mission Dengue Free India’, a nationwide disease awareness campaign aimed at strengthening community awareness, promoting preventive health behaviours and encouraging early recognition of dengue symptoms.
According to the National Centre for Vector Borne Disease Control (NCVBDC), more than 1.13 lakh dengue cases were officially reported across India in 2025However, experts believe the actual burden is likely to be higher, as many patients may not seek care at medical facilitiesIndia continues to account for nearly one-third of the global dengue burden, with seasonal outbreaks placing immense pressure on healthcare systems during the monsoon monthsWhile advances have been made in diagnosis and treatment, awareness around prevention, early symptom recognition and timely medical intervention remains inconsistent.
Recognising the need to move beyond treatment towards prevention, Fortis Healthcare and Takeda India have come together to drive a large-scale, evidence-based public awareness initiative that empowers individuals and communities with credible scientific information on dengue prevention and management.
The campaign brings together Fortis Healthcare’s extensive clinical expertise and nationwide hospital network with Takeda’s global scientific expertise in dengue prevention and public health education, creating a collaborative platform focused on improving health literacy and strengthening community preparedness.
As part of the campaign, Fortis Healthcare and Takeda India will roll out a series of physician-led awareness initiatives across selected Fortis hospitals and communitiesThese will include educational sessions for Resident Welfare Associations (RWAs), schools, colleges and corporates, expert-led public talks, doctor-authored articles, digital awareness campaigns, educational video podcasts, social media initiatives, hospital-based awareness programmes during the dengue season and dedicated digital resources These initiatives will help individuals recognise symptoms early, adopt preventive measures and seek timely medical care.
The campaign is designed to support the World Health Organization’s integrated approach to dengue prevention, which combines community education, vector control, timely diagnosis, appropriate case management and, where relevant and consistent with applicable national recommendations, vaccination to reduce the burden of the disease.
MrAnil Vinayak, Group COO, Fortis Healthcare, said, “At Fortis Healthcare, we believe our responsibility extends beyond treating illness to empowering communities with the knowledge they need to stay healthyDengue remains a significant public health concern in India, but greater awareness and timely action can help reduce the risk of infection and serious illness. Through ‘Mission Dengue Free India’, an initiative in collaboration with Takeda, we aim to equip individuals and families with credible, evidence-based information that promotes preventive practices, early recognition of symptoms and timely medical careSuch collaborations can broaden the reach of public health education, encourage community participation and support sustained dengue-prevention efforts.”
Mr Ted Kim, Country Head – India, Takeda Biopharmaceuticals, said, “At Takeda, we believe tackling dengue requires collective action across all sectors. Building on our global experience in dengue prevention and public health educationand Fortis Healthcare’s trusted clinical leadership, we aim to strengthen disease awareness, encourage preventive behaviours, and support India’s efforts to reduce the burden of dengue through education, preparedness and collaboration.”
The collaboration has been facilitated with the support of Mitsui & Co., which played an instrumental role in bringing together Fortis Healthcare and Takeda IndiaThe partnership reflects a shared vision of fostering innovative collaborations that contribute to improved public health outcomes through education and community engagement.
As India continues to witness recurring dengue outbreaks, both organisations believe hospitals have a critical role to play beyond clinical care by strengthening public awareness, improving health literacy, and supporting preventive healthcare. ‘Mission Dengue Free India’ represents an important step towards building better-informed communities and enhancing preparedness against dengue through sustained, collaborative action.
About Fortis Healthcare Limited
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in IndiaThe healthcare verticals of the company primarily comprise hospitals, diagnostics, and day care specialty facilitiesCurrently, the company operates 36 healthcare facilities (including JVs and O&M facilities) across 12 states and union territoriesThe Company’s network comprises over 6,150 operational beds (including O&M beds) and 400 diagnostics labs.
For more information, visit www.Fortishealthcare.com;
About Takeda India
Takeda is focused on creating better health for people and a brighter future for the worldWe aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccinesTogether with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipelineAs a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people, and the planetOur employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuriesIn India, Takeda operates as Takeda Biopharmaceuticals India Private Limitedandfocuses on core therapeutic areas including oncology, rare diseases, gastroenterology, and plasma-derived therapies, and vaccinesThrough its commercial presence, collaborations with local manufacturing partnerships, growing R&D capabilities, and the Innovation Capability Center (ICC), Takeda reinforces its long-term commitment to India and helps improve the lives of patients. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.
